oncotomskСибирский онкологический журналSiberian journal of oncology1814-48612312-3168Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences10.21294/1814-4861-2021-20-2-61-67oncotomsk-1756Research ArticleЛАБОРАТОРНЫЕ И ЭКСПЕРИМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯLABORATORY AND EXPERIMENTAL STUDIESМУЛЬТИПЛЕКСНОЕ ОПРЕДЕЛЕНИЕ ОНКОМАРКЕРОВ НА РАЗНЫХ СТАДИЯХ КОЛОРЕКТАЛЬНОГО РАКАMULTIPLEX DETECTION OF TUMOR MARKERS FOR DIFFERENT STAGES OF COLORECTAL CANCERhttps://orcid.org/0000-0001-5602-6136АхмалтдиноваЛ. Л.AkhmaltdinovaL. L.

 кандидат медицинских наук, заведующая лабораторией коллективного пользования научно-исследовательского центра

SPIN-код: 9212-3265. Researcher ID (WOS): B-8152-2018. Author ID (Scopus): 56285614700

 Казахстан, 100008, г. Караганда, ул. Гоголя, 40 

 PhD, Head of Laboratory

Researcher ID (WOS): B-8152-2018. Author ID (Scopus): 56285614700 

 40, Gogolya Street, Karaganda, 100008, Kazakhstan 

ahmaltdinova@qmu.kzhttps://orcid.org/0000-0001-6777-6864СиротаВ. Б.SirotaV. B.

 доктор медицинских наук, профессор кафедры онкологии

SPIN-код: 3667-1148 

 Казахстан, 100008, г. Караганда, ул. Гоголя, 40 

 MD, Professor, Oncology Department 

 40, Gogolya Street, Karaganda, 100008, Kazakhstan 

https://orcid.org/0000-0002-7221-5305ЖумалиеваВ. А.ZhumalievaV. A.

 доктор медицинских наук, ассистент профессора кафедры онкологии и лучевой диагностики 

 Казахстан, 100008, г. Караганда, ул. Гоголя, 40 

 MD, DSc, Department of Oncology and Diagnostic Imaging 

 40, Gogolya Street, Karaganda, 100008, Kazakhstan 

https://orcid.org/0000-0001-7173-3138КадыроваИ. А.KadyrovaI. A.

 доктор медицинских наук, старший научный сотрудник лаборатории коллективного пользования

SPIN-код: 2038-2991

 Казахстан, 100008, г. Караганда, ул. Гоголя, 40 

 MD, DSc, Senior Researcher 

 40, Gogolya Street, Karaganda, 100008, Kazakhstan 

https://orcid.org/0000-0003-2280-2146БабенкоД. Б.BabenkoD. B.

 доктор медицинских наук, директор научно-исследовательского центра

SPIN-код: 3567-2768. Researcher ID (WOS): P-8052-2017

 Казахстан, 100008, г. Караганда, ул. Гоголя, 40 

 MD, PhD, Director of Research Center

Researcher ID (WOS): P-8052-2017 

 40, Gogolya Street, Karaganda, 100008, Kazakhstan 

streampost@gmail.comhttps://orcid.org/0000-0001-5492-0046ТауешеваЗ. Б.TaueshevaZ. B.

 кандидат медицинских наук, ассистент профессора кафедры внутренних болезней № 1

SPIN-код: 6282-5045

 Казахстан, 100008, г. Караганда, ул. Гоголя, 40 

 MD, PhD, Department of Internal Diseases 

 40, Gogolya Street, Karaganda, 100008, Kazakhstan 

https://orcid.org/0000-0001-6971-8764ТайжановаД. Ж.TaizhanovaD. Zh.

 доктор медицинских наук, профессор, заведующая кафедрой внутренних болезней № 1

SPIN-код: 6295-5540

 Казахстан, 100008, г. Караганда, ул. Гоголя, 40 

 MD, Professor, Head of Department of Internal Diseases 

 40, Gogolya Street, Karaganda, 100008, Kazakhstan 

https://orcid.org/0000-0002-9968-9404ИбраеваА. С.IbraevaA. S.

стажер-исследователь научно-исследовательского центра

 Казахстан, 100008, г. Караганда, ул. Гоголя, 40 

 Researcher, Research Center 

 40, Gogolya Street, Karaganda, 100008, Kazakhstan 

aigera.tokpanova@mail.ruhttps://orcid.org/0000-0001-9122-1279АвдиенкоО. В.AvdienkoO. V.

 младший научный сотрудник научно-исследовательского центра

SPIN-код: 8822-3237

 Казахстан, 100008, г. Караганда, ул. Гоголя, 40 

 Junior Researcher, Research Center 

 40, Gogolya Street, Karaganda, 100008, Kazakhstan 

НАО «Медицинский университет Караганды»КазахстанKaraganda Medical UniversityKazakhstan2021290420212026167Copyright © Ахмалтдинова Л.Л., Сирота В.Б., Жумалиева В.А., Кадырова И.А., Бабенко Д.Б., Тауешева З.Б., Тайжанова Д.Ж., Ибраева А.С., Авдиенко О.В., 20212021Ахмалтдинова Л.Л., Сирота В.Б., Жумалиева В.А., Кадырова И.А., Бабенко Д.Б., Тауешева З.Б., Тайжанова Д.Ж., Ибраева А.С., Авдиенко О.В.Akhmaltdinova L.L., Sirota V.B., Zhumalieva V.A., Kadyrova I.A., Babenko D.B., Tauesheva Z.B., Taizhanova D.Z., Ibraeva A.S., Avdienko O.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.siboncoj.ru/jour/article/view/1756 Введение

 Введение. Колоректальный рак (КРР) занимает одно из ведущих мест в структуре онкологической заболеваемости, в том числе в азиатских странах. В Республике Казахстан прирост заболеваемости раком ободочной кишки за последнее десятилетие составил 23 %, раком прямой кишки  – 17 %. Несмотря на действующие программы скрининга  колоректального рака, продолжается поиск новых, в том числе сывороточных, маркеров для ранней диагностики, а у  пациентов с выявленным КРР – панелей маркеров для прогноза течения заболевания.

Целью исследования является изучение диагностической ценности и динамики сывороточных биомаркеров у больных КРР разных стадий.

Материал и методы

Материал и методы. Биомаркеры изучены  иммунофлуоресцентным методом с использованием технологии xMap, который включал в себя одновременное иммунофлуоресцентное определение на магнитных сферах CA125, CA15–3, CA19–9, CEA, CYFRA21–1, sFAS, sFasL, HE4,  Остеопонтин, VEGF-A, pd-L1.

Результаты

Результаты. Показано, что уровень исследованных  маркеров не имел значимых различий у здоровых лиц и у больных с неонкологической патологией толстой кишки. При КРР выявлена статистически значимая зависимость уровня только 2 биомаркеров – CEA и ОПН – от стадии заболевания. У больных КРР IV стадии наблюдается значимое повышение CA125 по сравнению с новообразованиями I–III стадий. Такие маркеры, как CA19–9, HE-4, CA15–3, CYFRA 21–1, наряду с CEA, могут быть предложены для применения в комплексной  диагностической панели. Полученные результаты  позволяют сделать вывод о диагностических перспективах  маркера pd-L1 при колоректальном раке. 

 Introduction

 Introduction. Colorectal cancer is one of the most common cancers worldwide. In the Republic of Kazakhstan, over the past decade, the incidence rates of colon and rectal cancers have increased by 23 % and 17 %, respectively. Although colorectal cancer screening rates have increased over time, it is necessary to identify new serum markers for early detection and prognosis of this cancer.

The aim of the study was to evaluate the  diagnostic value of serum biomarkers for colorectal cancer.

Material and Methods

Material and Methods. Biomarkers were studied by immunofluorescence method using xMap technology, which included simultaneous immunofluorescence determination on magnetic spheres CA125, CA15–3, CA19–9, CEA, CYFRA21–1, sFAS, sFasL, HE4, Osteopontin, VEGF-A, pd-L1.

Results

Results. The study showed no significant differences in the levels of markersbetween healthy subjects (control group) and patients with bowel diseases. In cancer patients, СEA and OpN markers increased with increasing tumor stage, and were significantly higher than those observed in patients with bowel diseases and controls. The CA125 marker was significantly higher in patients with stage IV cancer then in patients with I–III stages.

Conclusion

Conclusion. Our study revealed that the new pd-L1 marker can serve as a significant biomarker for colorectal cancer. 

колоректальный раконкомаркерыCEApD-L1остеопонтинcolorectal canceroncomarkerbiomarkerlaboratory diagnosticsCEApD-L1osteopontinРабота выполнена в рамках НТП О.0821 «Персонифицированный подход в управлении ряда значимых заболеваний», финансируемой МОН РК.The study was carried out within the framework of the program «Personalized approach to the management of diseases» funded by the Ministry of Education and Science of the Republic of Kazakhstan.ReferencesBrody H. Colorectal cancer. Nature. 2015 May 14; 521(7551): S1. doi: 10.1038/521S1a. PMID: 25970450.Brody H. Colorectal cancer. Nature. 2015 May 14; 521(7551): S1. doi: 10.1038/521S1a. PMID: 25970450.Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1; 136(5): E359–86. doi: 10.1002/ijc.29210.Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1; 136(5): E359–86. doi: 10.1002/ijc.29210.Одинцова И.Н., Черемисина О.В., Писарева Л.Ф., Спивакова И.О., Вусик М.В. Эпидемиология колоректального рака в Томской области. Сибирский онкологический журнал. 2017; 16(4): 89–95. doi: 10.21294/1814-4861-2017-16-4-89-95.Odintsova I.N., Cheremisina O.V., Pisareva L.F., Spivakova I.O., Vusik M.V. Epidemiology of colorectal cancer in Tomsk region. Siberian Journal of Oncology. 2017; 16(4): 89–95. (in Russian). doi: 10.21294/1814-4861-2017-16-4-89-95.Показатели онкологической службы Республики Казахстан за 2017 год (статистические материалы). КазНИИОиР. 2018. 128 с.Indicators of the cancer service of the Republic of Kazakhstan for 2017 (statistical materials). KIOR. 2018. 128 р. (in Russian).Дохдырбай М., Есентаева С.Е., Толеуханов Т.С., Бисмильдина Г.С., Умбетьярова Л.Б. Анализ заболеваемости колоректальным раком в Республике Казахстан в 2009–2013 гг. Вестник КазНМУ. 2016; 1: 704–709.Dokhdyrbai M., Esentaeva S.E., Toleukhanov T.S., Bismildina G.S., Umbetyarova L.B. Analysis of the incidence of colorectal cancer in the Republic of Kazakhstan in 2009–2013. KazNMU Bulletin. 2016; 1: 704–709. (in Russian).Yotsukura S., Mamitsuka H. Evaluation of serum-based cancer biomarkers: a brief review from a clinical and computational viewpoint. Crit Rev Oncol Hematol. 2015 Feb; 93(2): 103–15. doi: 10.1016/j.critrevonc.2014.10.002.Yotsukura S., Mamitsuka H. Evaluation of serum-based cancer biomarkers: a brief review from a clinical and computational viewpoint. Crit Rev Oncol Hematol. 2015 Feb; 93(2): 103–15. doi: 10.1016/j.critrevonc.2014.10.002.Lou E., Vogel R.I., Teoh D., Hoostal S., Grad A., Gerber M., Monu M., Lukaszewski T., Deshpande J., Linden M.A., Geller M.A. Assessment of Circulating Tumor Cells as a Predictive Biomarker of Histology in Women With Suspected Ovarian Cancer. Lab Med. 2018; 49(2): 134–9. doi: 10.1093/labmed/lmx084.Lou E., Vogel R.I., Teoh D., Hoostal S., Grad A., Gerber M., Monu M., Lukaszewski T., Deshpande J., Linden M.A., Geller M.A. Assessment of Circulating Tumor Cells as a Predictive Biomarker of Histology in Women With Suspected Ovarian Cancer. Lab Med. 2018; 49(2): 134–9. doi: 10.1093/labmed/lmx084.Voith von Voithenberg L., Crocetti E., Martos C., Dimitrova N., Giusti F., Randi G., Rooney R., Dyba T., Bettio M., Negrão Carvalho R. Cancer registries guardians of breast cancer biomarker information: A systematic review. Int J Biol Markers. 2019 Jun; 34(2): 194–199. doi: 10.1177/1724600819836097.Voith von Voithenberg L., Crocetti E., Martos C., Dimitrova N., Giusti F., Randi G., Rooney R., Dyba T., Bettio M., Negrão Carvalho R. Cancer registries guardians of breast cancer biomarker information: A systematic review. Int J Biol Markers. 2019 Jun; 34(2): 194–199. doi: 10.1177/1724600819836097.Otoshi T., Nagano T., Tachihara M., Nishimura Y. Possible Biomarkers for Cancer Immunotherapy. Cancers (Basel). 2019; 11(7): 935. doi: 10.3390/cancers1107093.Otoshi T., Nagano T., Tachihara M., Nishimura Y. Possible Biomarkers for Cancer Immunotherapy. Cancers (Basel). 2019; 11(7): 935. doi: 10.3390/cancers1107093.George A.P., Kuzel T.M., Zhang Y., Zhang B. The Discovery of Biomarkers in Cancer Immunotherapy. Comput Struct Biotechnol J. 2019 Apr 4; 17: 484–97. doi: 10.1016/j.csbj.2019.03.015.George A.P., Kuzel T.M., Zhang Y., Zhang B. The Discovery of Biomarkers in Cancer Immunotherapy. Comput Struct Biotechnol J. 2019 Apr 4; 17: 484–97. doi: 10.1016/j.csbj.2019.03.015.Pellino G., Gallo G., Pallante P., Capasso R., De Stefano A., Maretto I., Malapelle U., Qiu S., Nikolaou S., Barina A., Clerico G., Reginelli A., Giuliani A., Sciaudone G., Kontovounisios C., Brunese L., Trompetto M., Selvaggi F. Noninvasive Biomarkers of Colorectal Cancer: Role in Diagnosis and Personalised Treatment Perspectives. Gastroenterol Res Pract. 2018 Jun 13; 2018: 2397863. doi: 10.1155/2018/2397863.Pellino G., Gallo G., Pallante P., Capasso R., De Stefano A., Maretto I., Malapelle U., Qiu S., Nikolaou S., Barina A., Clerico G., Reginelli A., Giuliani A., Sciaudone G., Kontovounisios C., Brunese L., Trompetto M., Selvaggi F. Noninvasive Biomarkers of Colorectal Cancer: Role in Diagnosis and Personalised Treatment Perspectives. Gastroenterol Res Pract. 2018 Jun 13; 2018: 2397863. doi: 10.1155/2018/2397863.Nikolaou S., Qiu S., Fiorentino F., Rasheed S., Tekkis P., Kontovounisios C. Systematic review of blood diagnostic markers in colorectal cancer. Tech Coloproctol. 2018 Jul; 22(7): 481–498. doi: 10.1007/s10151-018-1820-3.Nikolaou S., Qiu S., Fiorentino F., Rasheed S., Tekkis P., Kontovounisios C. Systematic review of blood diagnostic markers in colorectal cancer. Tech Coloproctol. 2018 Jul; 22(7): 481–498. doi: 10.1007/s10151-018-1820-3.Tong G., Xu W., Zhang G., Liu J., Zheng Z, Chen Y., Niu P., Xu X. The role of tissue and serum carcinoembryonic antigen in stages I to III of colorectal cancer – A retrospective cohort study. Cancer Med. 2018; 7(11): 5327–38. doi: 10.1002/cam4.1814.Tong G., Xu W., Zhang G., Liu J., Zheng Z, Chen Y., Niu P., Xu X. The role of tissue and serum carcinoembryonic antigen in stages I to III of colorectal cancer – A retrospective cohort study. Cancer Med. 2018; 7(11): 5327–38. doi: 10.1002/cam4.1814.Huang R.H., Quan Y.J., Chen J.H., Wang T.F., Xu M., Ye M., Yuan H., Zhang C.J., Liu X.J., Min Z.J. Osteopontin Promotes Cell Migration and Invasion, and Inhibits Apoptosis and Autophagy in Colorectal Cancer by activating the p38 MAPK Signaling Pathway. Cell Physiol Biochem. 2017; 41(5): 1851–1864. doi: 10.1159/000471933.Huang R.H., Quan Y.J., Chen J.H., Wang T.F., Xu M., Ye M., Yuan H., Zhang C.J., Liu X.J., Min Z.J. Osteopontin Promotes Cell Migration and Invasion, and Inhibits Apoptosis and Autophagy in Colorectal Cancer by activating the p38 MAPK Signaling Pathway. Cell Physiol Biochem. 2017; 41(5): 1851–1864. doi: 10.1159/000471933.Kamal A., Darwish R.K., Saad S., Salama M., El-Baradie T.S, Mahmoud H.G., Elshiwy Y. Association of Osteopontin Gene Polymorphisms with Colorectal Cancer. Cancer Invest. 2017; 35(2): 71–7. doi: 10.1080/07357907.2016.1247454.Kamal A., Darwish R.K., Saad S., Salama M., El-Baradie T.S, Mahmoud H.G., Elshiwy Y. Association of Osteopontin Gene Polymorphisms with Colorectal Cancer. Cancer Invest. 2017; 35(2): 71–7. doi: 10.1080/07357907.2016.1247454.Wei R., Wong J.P.C., Kwok H.F. Osteopontin a promising biomarker for cancer therapy. J Cancer. 2017 Jul 15; 8(12): 2173–2183. doi: 10.7150/jca.20480.Wei R., Wong J.P.C., Kwok H.F. Osteopontin a promising biomarker for cancer therapy. J Cancer. 2017 Jul 15; 8(12): 2173–2183. doi: 10.7150/jca.20480.Peltonen R., Österlund P., Lempinen M., Nordin A., Stenman U.H., Isoniemi H. Postoperative CEA is a better prognostic marker than CA19-9, hCGβ or TATI after resection of colorectal liver metastases. Tumour Biol. 2018 Jan; 40(1): 1010428317752944. doi: 10.1177/1010428317752944.Peltonen R., Österlund P., Lempinen M., Nordin A., Stenman U.H., Isoniemi H. Postoperative CEA is a better prognostic marker than CA19-9, hCGβ or TATI after resection of colorectal liver metastases. Tumour Biol. 2018 Jan; 40(1): 1010428317752944. doi: 10.1177/1010428317752944.Yu Z., Chen Z., Wu J., Li Z., Wu Y. Prognostic value of pretreatment serum carbohydrate antigen 19-9 level in patients with colorectal cancer: A meta-analysis. PLoS One. 2017; 12(11): e0188139. doi: 10.1371/journal.pone.0188139.Yu Z., Chen Z., Wu J., Li Z., Wu Y. Prognostic value of pretreatment serum carbohydrate antigen 19-9 level in patients with colorectal cancer: A meta-analysis. PLoS One. 2017; 12(11): e0188139. doi: 10.1371/journal.pone.0188139.Kim N.H., Lee M.Y., Park J.H., Park D.I., Sohn C.I., Choi K., Jung Y.S. Serum CEA and CA 19-9 Levels are Associated with the Presence and Severity of Colorectal Neoplasia. Yonsei Med J. 2017 Sep; 58(5): 918–24. doi: 10.3349/ymj.2017.58.5.918.Kim N.H., Lee M.Y., Park J.H., Park D.I., Sohn C.I., Choi K., Jung Y.S. Serum CEA and CA 19-9 Levels are Associated with the Presence and Severity of Colorectal Neoplasia. Yonsei Med J. 2017 Sep; 58(5): 918–24. doi: 10.3349/ymj.2017.58.5.918.Liang S., Chang L. Serum matrix metalloproteinase-9 level as a biomarker for colorectal cancer: a diagnostic meta-analysis. Biomark Med. 2018 Apr; 12(4): 393–402. doi: 10.2217/bmm-2017-0206.Liang S., Chang L. Serum matrix metalloproteinase-9 level as a biomarker for colorectal cancer: a diagnostic meta-analysis. Biomark Med. 2018 Apr; 12(4): 393–402. doi: 10.2217/bmm-2017-0206.Thomas D.S., Fourkala E.O., Apostolidou S., Gunu R., Ryan A., Jacobs I., Menon U., Alderton W., Gentry-Maharaj A., Timms J.F. Evaluation of serum CEA, CYFRA21-1 and CA125 for the early detection of colorectal cancer using longitudinal preclinical samples. Br J Cancer. 2015 Jul 14; 113(2): 268–74. doi: 10.1038/bjc.2015.202.Thomas D.S., Fourkala E.O., Apostolidou S., Gunu R., Ryan A., Jacobs I., Menon U., Alderton W., Gentry-Maharaj A., Timms J.F. Evaluation of serum CEA, CYFRA21-1 and CA125 for the early detection of colorectal cancer using longitudinal preclinical samples. Br J Cancer. 2015 Jul 14; 113(2): 268–74. doi: 10.1038/bjc.2015.202.Gao Y., Wang J., Zhou Y., Sheng S., Qian S.Y., Huo X. Evaluation of Serum CEA, CA19-9, CA72-4, CA125 and Ferritin as Diagnostic Markers and Factors of Clinical Parameters for Colorectal Cancer. Sci Rep. 2018 Feb 9; 8(1): 2732. doi: 10.1038/s41598-018-21048-y.Gao Y., Wang J., Zhou Y., Sheng S., Qian S.Y., Huo X. Evaluation of Serum CEA, CA19-9, CA72-4, CA125 and Ferritin as Diagnostic Markers and Factors of Clinical Parameters for Colorectal Cancer. Sci Rep. 2018 Feb 9; 8(1): 2732. doi: 10.1038/s41598-018-21048-y.Chang S.J., Ge X.S., Xu Z.Y., Qi X.W., Chen X.P. Lower serum CA125 level, negative vascular invasion, and wild BRAF were strongly associated with better 2-year disease-free survival in patients with stage III colorectal cancer who received adjuvant chemotherapy. Cancer Biomark. 2018; 22(1): 161–8. doi: 10.3233/CBM-181179.Chang S.J., Ge X.S., Xu Z.Y., Qi X.W., Chen X.P. Lower serum CA125 level, negative vascular invasion, and wild BRAF were strongly associated with better 2-year disease-free survival in patients with stage III colorectal cancer who received adjuvant chemotherapy. Cancer Biomark. 2018; 22(1): 161–8. doi: 10.3233/CBM-181179.Huang C.J., Jiang J.K., Chang S.C., Lin J.K., Yang S.H. Serum CA125 concentration as a predictor of peritoneal dissemination of colorectal cancer in men and women. Medicine (Baltimore). 2016 Nov; 95(47): e5177. doi: 10.1097/MD.0000000000005177.Huang C.J., Jiang J.K., Chang S.C., Lin J.K., Yang S.H. Serum CA125 concentration as a predictor of peritoneal dissemination of colorectal cancer in men and women. Medicine (Baltimore). 2016 Nov; 95(47): e5177. doi: 10.1097/MD.0000000000005177.Kemal Y.N., Demirag G.N., Bedir A.M., Tomak L., Derebey M., Erdem D.L., Gör U., Yücel I. Serum human epididymis protein 4 levels in colorectal cancer patients. Mol Clin Oncol. 2017 Sep; 7(3): 481–485. doi: 10.3892/mco.2017.1332.Kemal Y.N., Demirag G.N., Bedir A.M., Tomak L., Derebey M., Erdem D.L., Gör U., Yücel I. Serum human epididymis protein 4 levels in colorectal cancer patients. Mol Clin Oncol. 2017 Sep; 7(3): 481–485. doi: 10.3892/mco.2017.1332.Cao H., Fang X., Li H., Li H., Kong J. Ultrasensitive detection of mucin 1 biomarker by immuno-loop-mediated isothermal amplification. Talanta. 2017 Mar 1; 164: 588–592. doi: 10.1016/j.talanta.2016.07.018.Cao H., Fang X., Li H., Li H., Kong J. Ultrasensitive detection of mucin 1 biomarker by immuno-loop-mediated isothermal amplification. Talanta. 2017 Mar 1; 164: 588–592. doi: 10.1016/j.talanta.2016.07.018.Attallah A.M., El-Far M., Ibrahim A.R., El-Desouky M.A., Omran M.M., Elbendary M.S., Attallah K.A., Qura E.R., Abdallah S.O. Clinical value of a diagnostic score for colon cancer based on serum CEA, CA19-9, cytokeratin-1 and mucin-1. Br J Biomed Sci. 2018; 75(3): 122–7. doi: 10.1080/09674845.2018.1456309.Attallah A.M., El-Far M., Ibrahim A.R., El-Desouky M.A., Omran M.M., Elbendary M.S., Attallah K.A., Qura E.R., Abdallah S.O. Clinical value of a diagnostic score for colon cancer based on serum CEA, CA19-9, cytokeratin-1 and mucin-1. Br J Biomed Sci. 2018; 75(3): 122–7. doi: 10.1080/09674845.2018.1456309.Goulart A., Ferreira C., Rodrigues A., Coimbra B., Sousa N., Leão P. The correlation between serum vascular endothelial growth factor (VEGF) and tumor VEGF receptor 3 in colorectal cancer. Ann Surg Treat Res. 2019 Jul; 97(1): 15–20. doi: 10.4174/astr.2019.97.1.15.Goulart A., Ferreira C., Rodrigues A., Coimbra B., Sousa N., Leão P. The correlation between serum vascular endothelial growth factor (VEGF) and tumor VEGF receptor 3 in colorectal cancer. Ann Surg Treat Res. 2019 Jul; 97(1): 15–20. doi: 10.4174/astr.2019.97.1.15.Xu H., Ren Y.J., Liu K., Min X.L., Yang L., Zhou Y., Zheng J., Yang C. Correlations of serum VEGF and MMP-2 levels with CLM in CRC patients and effects of TACE on their expressions. Eur Rev Med Pharmacol Sci. 2018 Jun; 22(11): 3394–3401. doi: 10.26355/eurrev_201806_15161.Xu H., Ren Y.J., Liu K., Min X.L., Yang L., Zhou Y., Zheng J., Yang C. Correlations of serum VEGF and MMP-2 levels with CLM in CRC patients and effects of TACE on their expressions. Eur Rev Med Pharmacol Sci. 2018 Jun; 22(11): 3394–3401. doi: 10.26355/eurrev_201806_15161.Karpuz T., Araz M., Korkmaz L., Kılınc I., Findik S., Karaagaç M., Eryilmaz M.K., Artac M. The Prognostic Value of Serum Semaphorin3A and VEGF Levels in Patients with Metastatic Colorectal Cancer. J Gastrointest Cancer. 2020 Jun; 51(2): 491–497. doi: 10.1007/s12029-019-00263-4.Karpuz T., Araz M., Korkmaz L., Kılınc I., Findik S., Karaagaç M., Eryilmaz M.K., Artac M. The Prognostic Value of Serum Semaphorin3A and VEGF Levels in Patients with Metastatic Colorectal Cancer. J Gastrointest Cancer. 2020 Jun; 51(2): 491–497. doi: 10.1007/s12029-019-00263-4.Chen H., Qian J., Werner S., Cuk K., Knebel P., Brenner H. Development and validation of a panel of five proteins as blood biomarkers for early detection of colorectal cancer. Clin Epidemiol. 2017; 9: 517–26. doi: 10.2147/CLEP.S144171.Chen H., Qian J., Werner S., Cuk K., Knebel P., Brenner H. Development and validation of a panel of five proteins as blood biomarkers for early detection of colorectal cancer. Clin Epidemiol. 2017; 9: 517–26. doi: 10.2147/CLEP.S144171.Sun C., Mezzadra R., Schumacher T.N. Regulation and Function of the PD-L1 Checkpoint. Immunity. 2018; 48(3): 434–52. doi: 10.1016/j.immuni.2018.03.014.Sun C., Mezzadra R., Schumacher T.N. Regulation and Function of the PD-L1 Checkpoint. Immunity. 2018; 48(3): 434–52. doi: 10.1016/j.immuni.2018.03.014.

The authors declare that there are no conflicts of interest present.